



Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference

May 11, 2026

SAN DIEGO--(BUSINESS WIRE)--May 11, 2026-- Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced two scientific posters for its lead investigational drug candidate, PIPE-791, at the upcoming American Thoracic Society (ATS) 2026 International Conference. ATS 2026 will take place in Orlando, Fla. from May 15-20, 2026.

The following abstracts are posted on ATS 2026's online itinerary planner for registered users.

Title: PIPE-791 and BMS-986278: Two Lysophosphatidic Acid Receptor 1 (LPA1) Antagonists With Distinct Lung Occupancy Profiles and Vascular Effects

Presenter: Daniel S. Lorrain, Ph.D., Chief Scientific Officer at Contineum Therapeutics

Poster: P155

Date and Time: Monday, May 18, 2026 from 11:30 a.m. ET-1:15 p.m. ET

Session: From Target Discovery to Clinical Translation in Pulmonary Fibrosis

Title: LPA1 Antagonism by PIPE-791 Reduces Alveolar Epithelial Cell Apoptosis In Vitro

Presenter: Michael Poon, Ph.D., VP, Biology at Contineum Therapeutics

Poster: P156

Date and Time: Monday, May 18, 2026 from 11:30 a.m. ET-1:15 p.m. ET

Session: From Target Discovery to Clinical Translation in Pulmonary Fibrosis

Posters will be available to view during ATS 2026 at the stated times for registered users and on the [Publications](#) page of Contineum's website.

About Contineum Therapeutics

Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis and chronic pain. PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis and major depressive disorder. For more information, please visit www.contineum-tx.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20260511897086/en/): <https://www.businesswire.com/news/home/20260511897086/en/>

Steve Kunszabo

Contineum Therapeutics

Senior Director, Investor Relations & Corporate Communications

858-649-1158

skunszabo@contineum-tx.com

Source: Contineum Therapeutics, Inc.